Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you approach patients with lymph node only recurrences in the setting of previously resected colon cancer that are not amenable to biopsy?
Do we wait and watch vs start treatment based on ctDNA results?
Related Questions
What is the data to guide salvage radiation to a patient with recurrence anal cancer to the lymph node after an initial definitive chemoradiation?
Do you regularly incorporate oral cryotherapy in your practice for patients receiving oxaliplatin to decrease the risk of thermal hyperalgesia?
What is your institutional practice for neoadjuvant therapy prior to transplanting cholangiocarcinoma?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
How do you integrate immunotherapy as a part of neoadjuvant treatment for MSI high stage III gastric carcinoma?
In the setting of total neoadjuvant therapy (TNT) for locally advanced rectal cancer, would you consider using FOLFIRI instead of FOLFOX/CAPOX for consolidative chemotherapy in patients unable to receive oxaliplatin, with the goal of maximizing the chance of clinical complete response and facilitating non-operative management?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
Would you administer adjuvant chemotherapy for extrahepatic cholangiocarcinoma that has received neoadjuvant therapy and achieved near CR?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?